---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-264043"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-06-09T21:19:56+00:00"
generated_at: "2026-06-09T21:22:37.846972+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Axsome shareholders elect directors, ratify Deloitte, approve say-on-pay at 2026 annual meeting

## Summary
- Mark Saad elected Class II director with 28,675,654 votes for, 10,286,822 withheld.
- Susan Mahony elected Class II director with 29,892,131 votes for, 9,070,345 withheld.
- Ratification of Deloitte & Touche as auditor passed with 43,278,147 votes for (98.9% of votes cast).
- Non-binding advisory vote on executive compensation approved with 37,818,384 votes for (97.5% of votes cast).
- Approximately 85.1% of outstanding shares were represented at the meeting.

## SEC filing metadata
- accession: 0001193125-26-264043
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-06-09T21:19:56+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/0001193125-26-264043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/axsm-20260605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-264043
- JSON: https://secwatch.observer/filing/0001193125-26-264043.json
- Plain text: https://secwatch.observer/filing/0001193125-26-264043.txt

## Key facts
- Shareholder Votes
  Axsome Therapeutics, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: Proposal 2: Ratification of Appointment of Deloitte & Touche LLP. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,278,147 14,407 484,982 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/0001193125-26-264043-index.htm
- Shareholder Votes
  Axsome Therapeutics, Inc. shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers at the 2026-06-05 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers. The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 37,818,384 777,937 366,155 4,815,060
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/0001193125-26-264043-index.htm
- Shareholder Votes
  Axsome Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: Proposal 1: Election of Class II Directors. The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the Class II directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Mark Saad 28,675,654 10,286,822 4,815,060 Susan Mahony, Ph.D., MBA 29,892,131 9,070,345 4,815,060
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000119312526264043/0001193125-26-264043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.